- BioVie Inc BIVI announced results from two Phase 2 trials assessing NE3107's potential in Parkinson's Disease (PD) and Alzheimer's Disease (AD).
- Parkinson's patients treated with the combination of NE3107 and levodopa improved their UPDRS Part 3 (motor) score, which is 3+ points superior to those treated with levodopa alone.
- Patients younger than 70 years old treated with NE3107 and levodopa experienced improvements that are roughly 6 points better than levodopa-treated alone. Patients younger than 70 years old represented roughly one-half of the study participants.
- Related: This Small Biotech Company Touts Promising Data For Alzheimer's Candidate.
- After 28 days of treatment, 63.6% of patients treated with levodopa alone experienced >30% improvement from Day 0 at the two-hour mark compared to 80% for NE3107+levodopa-treated patients and 88.9% of NE3107+levodopa patients under 70 years old.
- There were no drug-related adverse events.
- Full details from this trial will be presented at the upcoming Conference next year.
- The company also shared additional data from Alzheimer's trial, demonstrating enhanced cognition after three months of treatment with NE3107 compared to baseline.
- Patients showed improvement in daily function and reduced inflammation, with 18 of 22 patients with abnormal baseline scans showing improvement in one or more brain regions.
- Price Action: BIVI shares are up 16.10% at $6.05 during the premarket session on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.